UBS Group
CANF

UBS Group’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

UBS Group’s Portfolio CANF Stock Details CANF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.67K Buy
2,152
+1,105
+106% +$4.57K ﹤0.01% 8666
2025
Q4 		$4.19K Buy
1,047
+982
+1,511% +$7.7K ﹤0.01% 8878
2025
Q3 		$810 Sell
65
-211
-76% -$3.22K ﹤0.01% 9537
2025
Q2 		$5.79K Buy
+276
New +$6.36K ﹤0.01% 9136
2024
Q2 		– Sell
-109
Closed -$4.82K – 9560
2024
Q1 		$4.82K Buy
+109
New +$4.55K ﹤0.01% 7590
2023
Q2 		– Sell
-36
Closed -$1.64K – 8970
2023
Q1 		$1.64K Sell
36
-8
-18% -$575 ﹤0.01% 8688
2022
Q4 		$5.31K Sell
44
-43
-49% -$6.67K ﹤0.01% 9194
2022
Q3 		$13K Buy
87
+49
+129% +$8.49K ﹤0.01% 8010
2022
Q2 		$7K Buy
38
+2
+6% +$384 ﹤0.01% 8460
2022
Q1 		$9K Buy
+36
New +$8.31K ﹤0.01% 8533
2021
Q3 		– Sell
-39
Closed -$18K – 9568
2021
Q2 		$18K Buy
+39
New +$17.1K ﹤0.01% 7441
2020
Q3 		– Sell
-15
Closed -$6K – 8007
2020
Q2 		$6K Sell
15
-28
-65% -$10.3K ﹤0.01% 7283
2020
Q1 		$11K Buy
43
+39
+975% +$14.9K ﹤0.01% 6853
2019
Q4 		$2K Buy
+4
New +$2.15K ﹤0.01% 7820
2019
Q1 		– Sell
-1
Closed -$2K – 7751
2018
Q4 		$2K Buy
+1
New +$3.86K ﹤0.01% 7790
2018
Q3 		– Sell
-1
Closed -$3.75K – 7731
2018
Q2 		$3K Buy
+1
New +$3.99K ﹤0.01% 7619
2018
Q1 		– Hold
0
– -$1K – 7823
2017
Q4 		– Hold
0
– – – 7694
2017
Q3 		– Hold
0
– – – 7459
2017
Q1 		– Sell
-1
Closed -$6K – 7652
2016
Q4 		$6K Buy
+1
New +$7.01K ﹤0.01% 7145
2016
Q3 		– Sell
-2
Closed -$13.9K – 7504
2016
Q2 		$16K Buy
+2
New +$16.9K ﹤0.01% 6452
2015
Q3 		– Sell
-2
Closed -$11K – 8415
2015
Q2 		$11K Buy
2
+1
+100% +$7K ﹤0.01% 7379
2015
Q1 		$5K Buy
+1
New +$12K ﹤0.01% 8083
2014
Q4 		– Hold
0
– – – 9524

Other funds holding CANF

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

UBS Group's CANF Position: Q1 2026 in Review

UBS Group increased its Can-Fite BioPharma American Depositary Shares (CANF) stake by 106% in Q1 2026, buying an estimated $4.57K and bringing the position to 2,152 shares worth $6.67K. The position accounts for ﹤0.01% of the portfolio, ranked #8666.

UBS Group first reported a position in CANF in Q1 2015 and has held it in 20 quarters since. The position peaked at $18K in Q2 2021. 14 funds tracked by Wall St. Rank hold CANF as of Q1 2026.

  • UBS Group held 2,152 shares of Can-Fite BioPharma American Depositary Shares worth $6.67K as of Q1 2026.
  • UBS Group bought 1,105 Can-Fite BioPharma American Depositary Shares shares in Q1 2026, an estimated $4.57K.
  • Can-Fite BioPharma American Depositary Shares made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8666 holding.
  • UBS Group first reported a position in Can-Fite BioPharma American Depositary Shares in Q1 2015 and has held it in 20 quarters since.
  • UBS Group's Can-Fite BioPharma American Depositary Shares position peaked at $18K in Q2 2021.
  • 14 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.